Editorial: Combining chemo/radio therapy and immunotherapy for cancers-perfect mix of old and new

Clare Y Slaney; Peng Luo; Feng-Ming Kong; Linlang Guo; Jian Zhang

doi:10.3389/fimmu.2022.1129623

Editorial: Combining chemo/radio therapy and immunotherapy for cancers-perfect mix of old and new

Front Immunol. 2023 Jan 12:13:1129623. doi: 10.3389/fimmu.2022.1129623. eCollection 2022.

Authors

Clare Y Slaney^{1

2}, Peng Luo³, Feng-Ming Kong^{4

5}, Linlang Guo⁶, Jian Zhang³

Affiliations

¹ Cancer Immunology Program, Peter MacCallum Cancer Centre, Parkville, VIC, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
³ Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
⁴ Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong SAR, China.
⁵ Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
⁶ Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

No abstract available

Keywords: cancer; chemotherapy; combination therapy; immunotherapy; radiotherapy.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Combined Modality Therapy
Humans
Immunotherapy
Neoplasms* / therapy

Grants and funding

CS is supported by grants from the National Health and Medical Research Council (NHMRC) of Australia, the National Breast Cancer Foundation (NBCF) of Australia, mRNA Victoria, and Peter Mac Foundation.